Key facts
- Neurogram’s last known valuation is $203.0M (Jul 2025).
- It has raised $4.4M; the latest was Seed Round ($3.0M) in Jul 2025.
- Notable investors include Hustle Fund, Dorm Room Fund, Headline, Caffeinated Capital, Z Fellows — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Neurogram
- ·The full record, as it builds
Funding rounds
No funding rounds for Neurogram are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neurogram
Developer of a comprehensive electroencephalogram management platform designed to assist neurological diagnosis with advanced tools, enhancing the medical routine with agility and precision. The company platform offers high-technology ecosystems through artificial intelligence to detect and research neurological diseases and investigate the human brain, enabling doctors to detect neurological diseases at an early stage.
- Sector
- Healthcare
- HQ
- Atlanta, GA, United States
- Founded
- 2021
- Employees
- 20
- Website
- neurogram.com/
- Ownership
- Privately Held (backing)
Neurogram doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neurogram shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neurogram in its N-PORT filings yet. We sweep new filings monthly.